Literature DB >> 24438677

Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review.

X Huang1, F B Hollinger.   

Abstract

Occult hepatitis B (OHB) infection has been reported to play an important role in the development of hepatocellular carcinoma (HCC). In this systematic review, a significantly higher prevalence of OHB was observed in patients with HCC in the presence or absence of HCV infection when compared with control populations without HCC. Correspondingly, among adequately designed prospective studies, the cumulative probability of developing HCC was significantly greater among patients with OHB than among HBV DNA-negative patients in the presence or absence of HCV infection. Study design, inclusion criteria, treatment options, methodology and potential confounding variables were evaluated, and immunopathogenic mechanisms that could be involved in OHB as a risk factor in HCC were reviewed. From this analysis, we conclude that although OHB is an independent risk factor in HCC development in anti-HCV-negative patients, a synergistic or additive role in the occurrence of HCC in HCV-coinfected patients is more problematic due to the HCC risk attributable to HCV alone, especially in patients with advanced fibrosis and cirrhosis.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis C; hepatocellular carcinoma; incidence; occult hepatitis B; systematic review

Mesh:

Year:  2014        PMID: 24438677     DOI: 10.1111/jvh.12222

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  31 in total

1.  Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo.

Authors:  Chengliang Zhu; Hui Song; Fengxia Xu; Wei Yi; Fang Liu; Xinghui Liu
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

Review 2.  MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

Authors:  Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.

Authors:  Mahmoud Khattab; Magdy Fouad; Elham Ahmed
Journal:  World J Hepatol       Date:  2015-10-18

Review 4.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Authors:  Mindie H Nguyen; Grace Wong; Edward Gane; Jia-Horng Kao; Geoffrey Dusheiko
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

5.  High Prevalence of Hepatitis B Virus Infection in Young Adults in Ternate, Eastern Indonesia.

Authors:  Susan Irawati Ie; Erick Sidarta; Arkasha Sadhewa; Gludhug Ariyo Purnomo; Yuyun S M Soedarmono; Mochtar Zein Pattiiha; Meta Dewi Thedja; Alida R Harahap; David H Muljono
Journal:  Am J Trop Med Hyg       Date:  2015-09-21       Impact factor: 2.345

6.  Occult infection related hepatitis B surface antigen variants showing lowered secretion capacity.

Authors:  Hong Kim; Seoung-Ae Lee; You-Sub Won; HyunJoo Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

7.  MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis.

Authors:  Zhiyong Zhang; Wei Zheng; Jun Hai
Journal:  Med Oncol       Date:  2014-05-08       Impact factor: 3.064

Review 8.  Virus and Host Testing to Manage Chronic Hepatitis B.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

9.  Hepatitis B virus infection in children of HBV-related chronic liver disease patients: a study of intra-familial HBV transmission.

Authors:  Hartono Gunardi; Melanie Y Iskandar; Susan I Ie; Pramita G Dwipoerwantoro; Rino A Gani; David H Muljono
Journal:  Hepatol Int       Date:  2016-09-13       Impact factor: 6.047

10.  HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Yulan Wang; L I Zeng; Weiqing Chen
Journal:  Mol Clin Oncol       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.